Gannex Pharma Co., Ltd., a unit of Ascletis Pharma Inc. (ASCLF.PK) Tuesday reported positive interim results from the Phase 2 study of its drug candidate ASC41 to treat patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH).
In the Phase 2 study, patients are randomized to receive either ASC41 or placebo for 52-weeks. The interim analysis was conducted after 12-weeks.
At week 12, up to 93.3% patients who received ASC41, achieved at least a 30% relative reduction in liver fat content from baseline. The mean relative reduction in liver fat content from baseline was up to 68.2%.
Further, the company said adverse events were similar among patients receiving ASC41 treatment versus placebo.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.